Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte (INCY) PT Lowered to $60 at RBC Capital
May 1, 2024 6:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $60.00 (from $65.00) while maintaining a Sector Perform rating.
The analyst comments "On the surface, some choppiness for the key commercial franchises; Opzelura dynamics seem to be improving with the... More
Incyte (INCY) PT Lowered to $52 at BMO Capital
April 30, 2024 4:29 PM EDTBMO Capital analyst Evan David Seigerman lowered the price target on Incyte (NASDAQ: INCY) to $52.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Share response (-2%) follows a disappointing print, negative investor sentiment reflected in shares... More
